Sprint Bioscience AB (SE:SPRINT)

:SPRINT

SPRINT

Sprint Bioscience AB

RESEARCH TOOLSreports

Sprint Bioscience AB (SPRINT) Price & Analysis

1 Followers

SPRINT Stock Chart & Stats

kr1.48

-kr0.03(-2.43%)

At close: Mar 06 4:00 PM EST

kr1.48

-kr0.03(-2.43%)

Day’s Range― - ―

52-Week Rangekr0.36 - kr2.44

Previous CloseN/A

Volume19.16K

Average Volume (3M)560.98K

Market Cap

kr251.13M

Enterprise Valuekr124.42M

Total Cash (Recent Filing)kr126.70M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)1.5

Beta1.08

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.07

Shares Outstanding105,515,540

10 Day Avg. Volume1,502,692

30 Day Avg. Volume560,983

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr99.40M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free balance sheet materially reduces financial risk and interest burden, giving management flexibility to fund discovery work, negotiate licensing deals, or withstand delays. This structural strength supports long-term partnership negotiations and lowers bankruptcy risk.

2025 Profitability InflectionThe move from multi-year losses to substantial 2025 profitability demonstrates the company's ability to convert discovery work into partnerable, revenue-generating milestones. This validates the business model and improves cash runway and partner confidence over the medium term.

Partner/licensing-led Business ModelA licensing-focused model lets Sprint scale science without bearing late‑stage development costs, preserving capital and limiting operating leverage. Durable revenue levers (upfronts, milestones, royalties) diversify cash sources and align incentives with larger pharma partners.

Bears Say

Lumpy Cash FlowsDependence on milestone receipts and licensing timing causes persistent cash flow lumpiness. That undermines predictability for budgeting, can force dilutive financing or deal concessions in weak periods, and constrains steady reinvestment in the internal discovery pipeline.

Historical Equity InstabilityPrior low equity indicates sensitivity to funding shocks and past reliance on external capital. Even with current strength, this structural history signals vulnerability to adverse events and makes long-term planning dependent on continued successful deals or periodic financing.

Small Organizational ScaleA small headcount constrains simultaneous project throughput and internal capability breadth, increasing reliance on external partners and CROs. Over time, limited in‑house scale can slow pipeline diversification and make the business more sensitive to individual project setbacks.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was kr0.36 and its highest was kr2.44 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is kr251.13M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 42 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported kr1.073 earnings per share for the quarter, beating the consensus estimate of N/A by kr1.073.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of kr1.073 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in SE:SPRINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.